📋 Key Information Summary
- Waldenström macroglobulinaemia (WM) is a rare indolent lymphoplasmacytic lymphoma (LPL) characterised by bone marrow infiltration with clonal lymphoplasmacytic cells and secretion of monoclonal immunoglobulin M (IgM).
- The MYD88 L265P somatic mutation is present in >90% of WM cases and is a key diagnostic and potentially therapeutic target; CXCR4 WHIM-like mutations are found in ~30–40% and confer resistance to certain agents.
- Hyperviscosity syndrome is an oncological emergency — serum viscosity >4 cp or symptomatic patients require urgent plasmapheresis before chemotherapy.
- IgM-related neuropathy affects up to 20% of patients and may be the presenting feature; anti-MAG antibodies are implicated in distal sensory demyelinating neuropathy.
- Diagnosis requires bone marrow biopsy demonstrating ≥10% lymphoplasmacytic infiltration, immunophenotypic confirmation (CD19+, CD20+, CD5−, CD10−, CD23−), and identification of serum IgM monoclonal protein on serum protein electrophoresis (SPEP) and immunofixation.
- Ibrutinib (Imbruvica®) — a Bruton's tyrosine kinase inhibitor — is a first-line option for symptomatic WM, with or without rituximab; PBS Authority Required listing in Australia.
- Rituximab (MabThera®) is a cornerstone of combination therapy; commonly paired with cyclophosphamide, dexamethasone (DRC) or bendamustine (BR) for chemoimmunotherapy.
- Asymptomatic patients with low-level IgM and no cytopenias or hyperviscosity may be observed with watchful waiting.
- Treatment indications include symptomatic hyperviscosity, progressive cytopenias (Hb <100 g/L or platelets <100 × 10⁹/L), bulky disease, severe neuropathy, or cryoglobulinaemia.
- Venous thromboembolism risk is increased; IPCs and LMWH prophylaxis should be considered during immobility and chemotherapy.
- Incidence in Australia is approximately 0.5–0.6 per 100,000 population; median age at diagnosis 65–70 years, with a slight male predominance.
- Aboriginal and Torres Strait Islander peoples may present later due to access barriers; culturally safe, team-based care and health-literacy-appropriate education are essential.
Introduction & Australian Epidemiology
Waldenström macroglobulinaemia (WM) is a rare, indolent B-cell lymphoproliferative disorder classified as a lymphoplasmacytic lymphoma (LPL) by the World Health Organization (WHO). It is defined by the presence of bone marrow infiltration by clonal lymphoplasmacytic cells and evidence of an immunoglobulin M (IgM) monoclonal gammopathy. First described by Jan Gösta Waldenström in 1944, the disease occupies a unique niche between multiple myeloma and low-grade lymphomas.
In Australia, WM accounts for approximately 1–2% of all haematological malignancies. Cancer Australia data and state cancer registries suggest an age-standardised incidence of 0.5–0.6 per 100,000 persons per year, with approximately 150–200 new diagnoses annually. The median age at presentation is 65–70 years, and the male-to-female ratio is approximately 1.5:1. The disease is rare before age 40 and is slightly more common in individuals of Northern European descent.
The disease course is variable: many patients remain asymptomatic for years with stable IgM levels, while others develop progressive cytopenias, hyperviscosity syndrome, organomegaly, or debilitating neuropathy. Treatment decisions are guided by the presence of symptoms rather than IgM level alone. The landscape of WM management has been transformed over the past decade by targeted therapies, particularly Bruton's tyrosine kinase (BTK) inhibitors, and Australian patients have benefited from Pharmaceutical Benefits Scheme (PBS) listings of key agents.
Pathogenesis — MYD88 L265P Mutation
The molecular hallmark of WM is the somatic MYD88 L265P mutation, present in >90% of cases. MYD88 is an adaptor protein in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signalling pathways. The L265P gain-of-function mutation leads to constitutive activation of nuclear factor kappa B (NF-κB) through the IRAK1/IRAK4 complex, promoting malignant lymphoplasmacytic cell survival and proliferation.
MYD88 L265P is diagnostic: The presence of this mutation in the context of IgM monoclonal gammopathy supports the diagnosis of WM over other IgM-producing conditions such as IgM myeloma, marginal zone lymphoma, or chronic lymphocytic leukaemia.
Key Molecular Features
- MYD88 L265P: Found in >95% of WM cases. Constitutively activates BTK via the MYD88→IRAK1/4→NF-κB axis. This interaction is the basis for the efficacy of ibrutinib, which binds BTK at the Cys481 residue.
- CXCR4 WHIM-like mutations: Present in 30–40% of WM patients, predominantly in those with MYD88 L265P. These gain-of-function mutations increase CXCR4 surface expression and downstream AKT/ERK signalling, conferring resistance to ibrutinib and associated with higher IgM levels and symptomatic hyperviscosity.
- ARID1A, CD79B, TP53: Secondary mutations that may contribute to disease progression, transformation to aggressive lymphoma, or treatment resistance.
- Epigenetic dysregulation: Aberrant DNA methylation patterns and histone modification contribute to gene silencing and are under active investigation as therapeutic targets.
Pathophysiology of IgM-Related Complications
Monoclonal IgM exerts its pathological effects through several mechanisms:
- Hyperviscosity: IgM pentamers are the largest immunoglobulin class (~950 kDa). They aggregate red blood cells (rouleaux formation), increase serum viscosity, and impair microcirculatory blood flow, leading to neurological and haemorrhagic complications.
- Anti-myelin-associated glycoprotein (anti-MAG) neuropathy: IgM antibodies bind MAG on Schwann cell surfaces, disrupting myelin structure and causing a distal symmetric demyelinating sensorimotor neuropathy.
- Cryoglobulinaemia: Type I cryoglobulins (monoclonal IgM) precipitate at low temperatures, causing Raynaud phenomenon, skin ulceration, and glomerulonephritis.
- Amyloidosis (AL type): Rarely, IgM light chains form amyloid fibrils, depositing in kidneys, heart, nerves, and soft tissues.
- Cold agglutinin disease: IgM with anti-I specificity causes complement-mediated haemolysis, particularly in the cold.
Clinical Features — Hyperviscosity & Neuropathy
Up to 25% of WM patients are asymptomatic at diagnosis, detected incidentally through serum protein electrophoresis (SPEP). Symptomatic patients may present with one or more of the following syndromes:
Hyperviscosity Syndrome
Oncological emergency: Hyperviscosity syndrome requires urgent plasmapheresis. Delayed treatment may result in irreversible neurological damage, stroke, or fatal haemorrhage. Serum viscosity >4 cp (relative to water) or symptomatic patients warrant immediate intervention.
Mild
Early Hyperviscosity
Fatigue, mild headache, blurred vision, epistaxis, gingival bleeding. IgM typically 30–50 g/L.
Setting: Outpatient monitoring, consider plasmapheresis
Moderate
Established Hyperviscosity
Confusion, dizziness, visual disturbance (retinal vein engorgement, haemorrhages), tinnitus, mucosal bleeding. IgM typically 50–80 g/L.
Setting: Hospital admission, urgent plasmapheresis
Severe
Hyperviscosity Crisis
Stupor, seizures, focal neurological deficits, stroke, coma, massive GI or CNS haemorrhage. IgM typically >80 g/L. Serum viscosity >10 cp.
Setting: ICU, emergency plasmapheresis, airway protection
Peripheral Neuropathy
IgM-related neuropathy affects 15–20% of WM patients at diagnosis and up to 50% during the disease course. Two main patterns are recognised:
- Anti-MAG neuropathy (most common): Distal, symmetric, predominantly sensory demyelinating neuropathy. Patients present with numbness, tingling, and gait unsteadiness, often beginning in the lower limbs. Anti-MAG antibodies are detectable in ~50% of WM neuropathy cases. Deep tendon reflexes are diminished, and sensory ataxia may be prominent.
- Axonal neuropathy: Less common; may be related to direct endoneurial deposition of IgM or amyloid. Presents with weakness and pain alongside sensory symptoms.
Anti-MAG testing: Request anti-MAG antibodies (ELISA) in any patient with IgM monoclonal gammopathy and peripheral neuropathy. Positive titres >1,500 BTU support the diagnosis. Nerve conduction studies should show prolonged distal motor latencies and reduced conduction velocities consistent with demyelination.
Other Presentations
- Cytopenias: Anaemia (Hb <100 g/L) is the most common finding at diagnosis. Thrombocytopenia and neutropaenia result from marrow infiltration or autoimmune mechanisms.
- Organomegaly: Hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%) are less prominent than in other lymphomas.
- B symptoms: Fever, night sweats, and unexplained weight loss occur in 10–15%.
- Bing–Neel syndrome: Direct CNS infiltration by malignant lymphoplasmacytic cells causing confusion, cranial nerve palsies, or spinal cord compression. A rare but devastating complication.
- Renal involvement: Light-chain deposition disease, cryoglobulinaemic glomerulonephritis, or amyloidosis may cause nephrotic syndrome or renal impairment.
- Skin: Schnitzler syndrome (chronic urticaria, monoclonal IgM, fever, arthralgia, bone pain) and cold-agglutinin-related acrocyanosis.
Investigations — SPEP, Bone Marrow Biopsy & Beyond
Diagnostic Criteria (IPWMWS / WHO 2022)
The diagnosis of WM requires all of the following:
- Any amount of serum IgM monoclonal protein (detected by SPEP and immunofixation)
- Bone marrow biopsy showing ≥10% infiltration by small lymphocytes, plasmacytoid lymphocytes, and plasma cells with an interstitial, nodular, or diffuse pattern
- Immunophenotypic evidence of LPL: CD19+, CD20+, surface IgM+, CD5−, CD10−, CD23− (typically; variations occur)
- Absence of features diagnostic of other lymphomas or multiple myeloma
Essential Investigations
Essential
Serum Protein Electrophoresis (SPEP) + Immunofixation (IFE)
Quantifies IgM monoclonal spike; IFE confirms heavy-chain isotype. MBS Item 66828. Serum IgM quantitation (nephelometry) for serial monitoring.
Essential
Bone Marrow Biopsy & Aspirate
Morphology, immunohistochemistry (CD20, CD138, CD5, CD10, CD23, cyclin D1), flow cytometry, MYD88 L265P mutation analysis (PCR or next-generation sequencing). MBS Item 13723.
Available
MYD88 L265P Mutation Testing
PCR-based allele-specific assay on bone marrow or peripheral blood; sensitivity >90% from marrow, ~80% from blood. Available at major tertiary centres and commercial labs (Sonic, Douglass Hanly Moir). Not currently separately MBS-billed.
Available
CXCR4 WHIM Mutation Testing
Next-generation sequencing panel; available at select molecular haematology laboratories (Peter MacCallum, Westmead). Predicts ibrutinib resistance. Research/unfunded.
Available
Serum Viscosity
Measured in centipoise (cp); normal 1.4–1.8 cp. Hyperviscosity symptoms usually appear at >4 cp. Available at major hospital biochemistry labs.
Available
Anti-MAG Antibodies
ELISA; positive >1,000 BTU supports anti-MAG neuropathy. Available at commercial immunology labs. MBS-rebatable under specialist request.
Essential
FBC, Renal Function, LFTs, LDH, β2-microglobulin, Free Light Chains
Baseline and for staging/prognostication. β2-microglobulin is an independent prognostic factor. Standard MBS items.
Available
CT Chest/Abdomen/Pelvis + PET-CT
Assessment of lymphadenopathy and extramedullary disease. PET-CT may identify Bing–Neel syndrome or transformation to aggressive lymphoma.
Referral
Nerve Conduction Studies (NCS) / EMG
Indicated when neuropathy suspected. Prolonged distal motor latencies, conduction block, and temporal dispersion suggest demyelinating pattern. Request through neurology or clinical neurophysiology.
Available
Cryoglobulins, Cold Agglutinins, Direct Antiglobulin Test (DAT)
Cryoglobulins require warm-sample handling (37°C transport). Cold agglutinin titre and thermal amplitude if haemolysis suspected.
Referral
Dilated Fundoscopy / Retinal Photography
Mandatory if hyperviscosity suspected. Findings include venous dilation, retinal haemorrhages, papilloedema. Urgent ophthalmology referral.
Risk Stratification & Prognostic Scoring
International Prognostic Scoring System for WM (IPSSWM / Revised IPSSWM)
| Risk Group | Criteria | Median OS |
|---|---|---|
| Low risk | Age ≤65 AND β2-microglobulin <3 mg/L AND Hb ≥115 g/L | Not reached (>15 years) |
| Intermediate risk | Any factor: age >65, β2-microglobulin 3–5.5 mg/L, Hb <115 g/L (but not high risk) | ~9–12 years |
| High risk | β2-microglobulin >5.5 mg/L | ~3–5 years |
Additional Prognostic Factors
- CXCR4 mutations: Associated with higher IgM levels, increased hyperviscosity risk, and reduced response to ibrutinib monotherapy.
- TP53 mutations/deletion: Predict poorer outcomes with chemoimmunotherapy; may favour targeted therapy approaches.
- LDH elevation: May indicate transformation to aggressive lymphoma (DLBCL).
- IgM >60 g/L: Higher risk of hyperviscosity; monitor closely even if asymptomatic.
Management — Ibrutinib, Rituximab & Plasmapheresis
Treatment Indications
Treatment should be initiated for symptomatic disease. Watchful waiting is appropriate for asymptomatic patients with low-level IgM and preserved blood counts.
Initiate treatment when any of the following are present:
- Symptomatic hyperviscosity
- Progressive cytopenias (Hb <100 g/L or platelets <100 × 10⁹/L) due to marrow infiltration
- Moderate-to-severe neuropathy (functional impairment)
- Bulky or symptomatic lymphadenopathy / organomegaly
- Systemic symptoms (B symptoms) attributable to WM
- Symptomatic cryoglobulinaemia or cold agglutinin disease
- AL amyloidosis
- Rapidly rising IgM (doubling time <6 months)
Emergency Management — Plasmapheresis
Plasmapheresis is first-line for hyperviscosity crisis. It rapidly reduces serum IgM by 50–75% and viscosity by 60–80%. One to three sessions (40–60 mL/kg exchange volume per session) are typically required. This is a bridge to definitive anti-tumour therapy, not a standalone treatment. Albumin (4–5%) is the standard replacement fluid.
Targeted Therapy — BTK Inhibitors
Ibrutinib
Imbruvica® · Bruton's tyrosine kinase (BTK) inhibitor
Adult dose
420 mg PO once daily, continuous until progression or unacceptable toxicity
Paediatric dose
Not established for WM; used in paediatric leukaemia protocols under specialist supervision
Key toxicities
Atrial fibrillation (7–15%), bleeding (bruising, major haemorrhage 2–4%), hypertension, arthralgias, infection risk
Renal adjustment
No dose adjustment for CrCl ≥25 mL/min; avoid if CrCl <25 mL/min (limited data)
Hepatic adjustment
Avoid in severe hepatic impairment (Child-Pugh C); reduce to 140 mg daily in moderate impairment
Interactions
Avoid concurrent strong CYP3A4 inhibitors (ketoconazole, clarithromycin) or inducers (rifampicin, carbamazepine). Hold 3–7 days pre-procedure for major bleeding risk.
PBS status
⚠ PBS Authority Required
Zanubrutinib
Brukinsa® · Next-generation BTK inhibitor
Adult dose
160 mg PO BD or 320 mg PO once daily, continuous
Key advantage
Higher BTK occupancy, less off-target kinase inhibition (EGFR, ITK, TEC); lower rates of atrial fibrillation and major bleeding vs ibrutinib in ASPEN trial
PBS status
⚠ PBS Authority Required
Monoclonal Antibody — Rituximab
Rituximab
MabThera® · Biosimilars available · Anti-CD20 monoclonal antibody
Adult dose
375 mg/m² IV weekly × 4 (induction), then 375 mg/m² IV every 2–3 months (maintenance) or as part of combination regimen
IgM flare
Warning: Rituximab can cause an initial rise in IgM ("IgM flare") of 25–50% in the first 1–3 months, potentially precipitating hyperviscosity. Pre-treat with plasmapheresis if IgM >40 g/L. Avoid as monotherapy in high-IgM patients.
PBS status
✔ PBS General Benefit (biosimilars available)
Chemoimmunotherapy Regimens
| Regimen | Components | Cycle | Notes |
|---|---|---|---|
| DRC | Dexamethasone 20 mg PO D1–4, Rituximab 375 mg/m² IV D1, Cyclophosphamide 100 mg/m² PO D1–5 | Every 21 days × 6 cycles | Well-tolerated first-line option. PBS-listed components. |
| BR | Bendamustine 90 mg/m² IV D1–2, Rituximab 375 mg/m² IV D1 | Every 28 days × 6 cycles | Higher overall response rate (~95%) vs DRC. More myelosuppression. PBS Authority Required for bendamustine. |
| Ibrutinib + Rituximab | Ibrutinib 420 mg PO daily + Rituximab 375 mg/m² IV weekly × 4 then monthly × 4 | Continuous ibrutinib; rituximab as above | iNNOVATE trial showed superior PFS vs rituximab alone. Preferred for elderly/comorbid patients. Avoid in patients with uncontrolled AF. |
| Bortezomib-based | Bortezomib 1.6 mg/m² IV D1, 8, 15 + Dexamethasone 20 mg + Rituximab 375 mg/m² | Every 28 days × 6 cycles | Rapid response; useful for urgent IgM reduction. Peripheral neuropathy risk limits duration. PBS Authority Required. |
Other Agents
Bendamustine
Ribomustin® · Alkylating agent
Adult dose
90 mg/m² IV D1–2 (with rituximab) every 28 days
Renal adjustment
Caution if CrCl <40 mL/min; limited data
PBS status
⚠ PBS Authority Required
Bortezomib
Velcade® · Proteasome inhibitor
Adult dose
1.3 mg/m² IV or SC on D1, 4, 8, 11 of 21-day cycle; or 1.6 mg/m² IV weekly
Key toxicity
Peripheral neuropathy (dose-limiting), thrombocytopaenia, herpes zoster reactivation — antiviral prophylaxis essential (valaciclovir 500 mg PO daily)
PBS status
⚠ PBS Authority Required
Cyclophosphamide
Endoxan® · Alkylating agent
Adult dose (DRC)
100 mg/m² PO D1–5 of 21-day cycle (with dexamethasone + rituximab)
PBS status
✔ PBS General Benefit
Treatment Algorithm
1
Symptomatic Hyperviscosity?
Yes → Emergency plasmapheresis (1–3 sessions) then initiate anti-tumour therapy. No → Assess other treatment indications.
2
Treatment-Naïve, Fit for Chemoimmunotherapy
Preferred: BR × 6 cycles or DRC × 6 cycles. Consider ibrutinib + rituximab if neuropathy predominates (avoid bortezomib) or if patient preference for oral therapy.
3
Elderly / Comorbid Patients
Ibrutinib monotherapy or ibrutinib + rituximab. Consider zanubrutinib if AF risk is a concern. Avoid bendamustine if ECOG >2 or significant cytopenias.
4
Relapsed / Refractory
Switch BTK inhibitor class if progressed on ibrutinib (zanubrutinib or acalabrutinib — if available). Alternative: bortezomib-rituximab, bendamustine-rituximab, or carfilzomib-based if available. Consider clinical trial enrolment.
Anticoagulation and BTK inhibitors: Concurrent use of ibrutinib/zanubrutinib with warfarin is contraindicated due to bleeding risk. DOACs may be used with caution; consult haematology. Hold BTK inhibitor 3–7 days before and after invasive procedures. Document an anticoagulation plan in the patient's medical record.
Monitoring
Response Assessment (IWWM Consensus Criteria)
| Response | Criteria |
|---|---|
| Complete Response (CR) | Negative immunofixation, no histological evidence of disease, resolution of extramedullary disease |
| Very Good Partial Response (VGPR) | ≥90% reduction in serum IgM from baseline |
| Partial Response (PR) | 50–89% reduction in serum IgM from baseline |
| Minor Response (MR) | 25–49% reduction in serum IgM from baseline |
| Stable Disease (SD) | <25% change in IgM, no new disease features |
| Progressive Disease (PD) | ≥25% increase in IgM (confirmed × 2, ≥12 weeks apart) or new cytopenias, organomegaly, or hyperviscosity |
Follow-Up Schedule
- During active treatment: FBC, serum IgM, viscosity every 2–4 weeks. LFTs, renal function each cycle.
- On maintenance / post-treatment: FBC, serum IgM, viscosity every 3 months for 2 years, then every 6 months if stable.
- Annual: Bone marrow biopsy if deep response assessment needed (e.g., for clinical trial or CR assessment). CT or PET-CT if extramedullary disease was present.
- On ibrutinib/zanubrutinib: ECG at baseline and if symptoms of AF develop. Blood pressure monitoring at each visit. Full blood count for cytopenias. Screen for second malignancies annually.
- Neuropathy: Serial NCS every 6–12 months if anti-MAG positive. Functional assessment (INCAT disability score).
Special Populations
Pregnancy
All chemotherapy and targeted agents
Teratogenic — avoid during pregnancy. WM is rare in women of childbearing age. If diagnosed in pregnancy: watchful waiting if asymptomatic; plasmapheresis for hyperviscosis (safe); rituximab may be considered in the second/third trimester if life-threatening disease.
Ibrutinib / Zanubrutinib
Category D — teratogenic in animal studies. Contraception mandatory during and for 1 month after cessation.
Paediatrics
General
WM is exceedingly rare in children. Paediatric LPL cases should be managed at a quaternary paediatric haematology centre (e.g., Royal Children's Hospital Melbourne, Sydney Children's Hospital). Treatment extrapolated from adult data; consider clinical trial enrolment.
Elderly (≥75 years)
Ibrutinib / Zanubrutinib monotherapy
Preferred first-line option in frail elderly. Avoid intensive chemoimmunotherapy (BR, BDR) if ECOG ≥3 or significant comorbidities. Geriatric assessment tools (GA scale, CIRS-G) should guide treatment intensity.
AF risk
Age >75 is an independent risk factor for BTK inhibitor–associated atrial fibrillation. Baseline ECG mandatory. Zanubrutinib preferred if AF concern.
Renal Impairment
Cyclophosphamide
Reduce dose by 25% if CrCl <25 mL/min.
Bendamustine
Use with caution if CrCl <40 mL/min; limited safety data.
Ibrutinib
No adjustment for CrCl ≥25 mL/min. Avoid if CrCl <25 mL/min.
Hepatic Impairment
Ibrutinib
Reduce to 140 mg daily in moderate impairment (Child-Pugh B). Avoid in severe impairment (Child-Pugh C).
Rituximab
No dose adjustment; use with caution in hepatitis B carriers — screen HBsAg and anti-HBc before treatment. Antiviral prophylaxis (entecavir) if HBsAg+.
Immunocompromised
Infection prophylaxis
Hypogammaglobulinaemia is common in WM. Monitor IgG levels; consider IVIg replacement if IgG <4 g/L with recurrent infections (PBS-listed). Valaciclovir 500 mg PO daily for HSV/VZV prophylaxis with bortezomib. Trimethoprim-sulfamethoxazole for PCP prophylaxis if prolonged lymphopaenia. Annual influenza and COVID-19 vaccination. Pneumococcal vaccination (PCV20 or PCV13 → PPSV23) as per ATAGI schedule.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinaemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinaemia. Semin Oncol. 2003;30(2):110-115.
- 2. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinaemia. N Engl J Med. 2012;367(9):826-833.
- 3. Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinaemia. Blood. 2014;123(18):2791-2796.
- 4. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410.
- 5. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050.
- 6. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinaemia. Blood. 2016;128(10):1321-1328.
- 7. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30(2):116-120.
- 8. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Canberra: AIHW; 2024. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia
- 9. Riva M, Ferreri AJM, Motta V, et al. Bing-Neel syndrome: an update. Haematologica. 2017;102(2):e58-e60.
- 10. Department of Health and Aged Care. Pharmaceutical Benefits Scheme: ibrutinib. Canberra: Australian Government; 2024. Available from: https://www.pbs.gov.au/
- 11. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023.
- 12. Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(7):1104-1115.